Bioatla to participate in the 41st annual j.p. morgan healthcare conference

San diego, dec. 22, 2022 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will participate in a fireside chat and one-on-one investor meetings at the 41st annual j.p. morgan healthcare conference, to be held in san francisco, ca january 9-12, 2023.
BCAB Ratings Summary
BCAB Quant Ranking